NCT05117866View on ClinicalTrials.gov

Acetyl Salicylic Elimination Trial JAPAN: The ASET JAPAN Pilot Study

NAActive, not recruitingINTERVENTIONAL
Enrollment

307

Participants

Timeline

Start Date

September 15, 2020

Primary Completion Date

July 31, 2024

Study Completion Date

December 31, 2025

Conditions
Chronic Coronary SyndromeNon ST Segment Elevation Acute Coronary Syndrome
Interventions
DRUG

prasugrel Monotherapy

Prasugrel Monotherapy according to the local dosage (Loading : 20mg, maintenance: 3.75mg/day)

Trial Locations (13)

Unknown

CORRIB Research Centre for Advanced Imaging and Core laboratoryNational University of Ireland, Galway, Galway

Fujita Health University, Okazaki Medical Centre, Okazaki

Sapporo Higashi Tokushukai Hospital, Sapporo

Iwate Medical University Hopsital, Morioka

St. Marianna University School of Medicine Hospital, Kawasaki

JCHO Hoshigaoka Medical center, Hirakata

Kinki University Hospital, Faculty of Medicine, Ōsaka-sayama

Yamaguchi University Hospital, Ube

Mitusi Memorial Hospital, Tokyo

St. Luke's international hospital, Tokyo

Teikyo University Hospital, Tokyo

Toho University Ohashi Medical Center, Tokyo

470-1192

Fujita Health University, Toyoake

Sponsors

Lead Sponsor

Meditrix Corp
All Listed Sponsors
collaborator

Fujita Health University

OTHER

collaborator

Boston Scientific Japan K.K.

INDUSTRY

collaborator

National University of Ireland, Galway, Ireland

OTHER

lead

Meditrix Corp

INDUSTRY

NCT05117866 - Acetyl Salicylic Elimination Trial JAPAN: The ASET JAPAN Pilot Study | Biotech Hunter | Biotech Hunter